Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. (SHA:603168)
China
· Delayed Price · Currency is CNY 7.21
-0.08 (-1.10%)
Mar 11, 2026, 3:00 PM CST
SHA:603168 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 463.32 | 472.1 | 638.03 | 539.77 | 627.6 | 346.81 | Upgrade
|
| Other Revenue | 11.86 | 11.86 | 6.94 | 9.77 | 2.16 | - | Upgrade
|
| Revenue | 475.19 | 483.96 | 644.97 | 549.54 | 629.76 | 346.81 | Upgrade
|
| Revenue Growth (YoY) | -6.01% | -24.96% | 17.37% | -12.74% | 81.59% | -32.78% | Upgrade
|
| Cost of Revenue | 235.96 | 252.67 | 288.12 | 233.57 | 232.59 | 157.97 | Upgrade
|
| Gross Profit | 239.22 | 231.29 | 356.85 | 315.97 | 397.18 | 188.84 | Upgrade
|
| Selling, General & Admin | 204.04 | 225.31 | 268.63 | 206.47 | 243.41 | 223.44 | Upgrade
|
| Research & Development | 27.67 | 57.58 | 64.45 | 59.61 | 102.21 | 26.91 | Upgrade
|
| Other Operating Expenses | 2.18 | 4.96 | 6.16 | 5.94 | 8.24 | 3.74 | Upgrade
|
| Operating Expenses | 235.61 | 289.02 | 336.15 | 276.34 | 355.58 | 253.76 | Upgrade
|
| Operating Income | 3.61 | -57.73 | 20.71 | 39.62 | 41.6 | -64.93 | Upgrade
|
| Interest Expense | -8.19 | -8.3 | -4.61 | -1.64 | -0.77 | - | Upgrade
|
| Interest & Investment Income | 1.76 | 1.92 | 17.41 | 3.08 | 9.63 | 14.92 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.21 | -0.23 | -0.27 | -0.18 | -0.11 | 23.2 | Upgrade
|
| EBT Excluding Unusual Items | -3.03 | -64.35 | 33.23 | 40.87 | 50.35 | -26.8 | Upgrade
|
| Impairment of Goodwill | -33.34 | -33.34 | -13.3 | -9.48 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -26.91 | -16.92 | 1.19 | 6.97 | 2.64 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 1.67 | 1.05 | -0.01 | 15.82 | -0.21 | -0.55 | Upgrade
|
| Asset Writedown | -3.6 | - | - | - | - | -24.76 | Upgrade
|
| Legal Settlements | -1.4 | -1.4 | -2.76 | - | - | - | Upgrade
|
| Other Unusual Items | -0.61 | -0.61 | 14.73 | -0.17 | -3.9 | - | Upgrade
|
| Pretax Income | -67.22 | -115.57 | 33.08 | 54.01 | 48.87 | -52.11 | Upgrade
|
| Income Tax Expense | -1.75 | 5.92 | 7.97 | 9.26 | 13.22 | 2.86 | Upgrade
|
| Earnings From Continuing Operations | -65.47 | -121.49 | 25.1 | 44.75 | 35.66 | -54.98 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | - | -124.39 | Upgrade
|
| Net Income to Company | -65.47 | -121.49 | 25.1 | 44.75 | 35.66 | -179.37 | Upgrade
|
| Minority Interest in Earnings | 0.41 | -1.95 | 0.3 | -0 | - | - | Upgrade
|
| Net Income | -65.05 | -123.44 | 25.41 | 44.75 | 35.66 | -179.37 | Upgrade
|
| Net Income to Common | -65.05 | -123.44 | 25.41 | 44.75 | 35.66 | -179.37 | Upgrade
|
| Net Income Growth | - | - | -43.23% | 25.51% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 380 | 373 | 363 | 320 | 324 | 320 | Upgrade
|
| Shares Outstanding (Diluted) | 380 | 373 | 363 | 320 | 324 | 320 | Upgrade
|
| Shares Change (YoY) | 3.45% | 2.63% | 13.55% | -1.39% | 1.20% | -18.47% | Upgrade
|
| EPS (Basic) | -0.17 | -0.33 | 0.07 | 0.14 | 0.11 | -0.56 | Upgrade
|
| EPS (Diluted) | -0.17 | -0.33 | 0.07 | 0.14 | 0.11 | -0.56 | Upgrade
|
| EPS Growth | - | - | -50.00% | 27.27% | - | - | Upgrade
|
| Free Cash Flow | -18.2 | -102.43 | -178.3 | -32.97 | -52.66 | 26.91 | Upgrade
|
| Free Cash Flow Per Share | -0.05 | -0.28 | -0.49 | -0.10 | -0.16 | 0.08 | Upgrade
|
| Dividend Per Share | - | - | 0.021 | 0.037 | - | - | Upgrade
|
| Dividend Growth | - | - | -43.24% | - | - | - | Upgrade
|
| Gross Margin | 50.34% | 47.79% | 55.33% | 57.50% | 63.07% | 54.45% | Upgrade
|
| Operating Margin | 0.76% | -11.93% | 3.21% | 7.21% | 6.61% | -18.72% | Upgrade
|
| Profit Margin | -13.69% | -25.51% | 3.94% | 8.14% | 5.66% | -51.72% | Upgrade
|
| Free Cash Flow Margin | -3.83% | -21.17% | -27.64% | -6.00% | -8.36% | 7.76% | Upgrade
|
| EBITDA | 67.09 | 6.18 | 85.2 | 97.97 | 97.09 | 0.12 | Upgrade
|
| EBITDA Margin | 14.12% | 1.28% | 13.21% | 17.83% | 15.42% | 0.03% | Upgrade
|
| D&A For EBITDA | 63.48 | 63.91 | 64.49 | 58.35 | 55.49 | 65.04 | Upgrade
|
| EBIT | 3.61 | -57.73 | 20.71 | 39.62 | 41.6 | -64.93 | Upgrade
|
| EBIT Margin | 0.76% | -11.93% | 3.21% | 7.21% | 6.61% | -18.72% | Upgrade
|
| Effective Tax Rate | - | - | 24.11% | 17.14% | 27.05% | - | Upgrade
|
| Revenue as Reported | 475.19 | 483.96 | 644.97 | 549.54 | 629.76 | 358.23 | Upgrade
|
| Advertising Expenses | - | 6.9 | 1.86 | 2.62 | 4.47 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.